PROJECT SUMMARY
Cellular senescence and deregulated nutrient sensing (insulin signaling and/or insulin resistance), two hallmarks
of aging, are implicated in the loss of physiological function and etiology of age-related diseases. Advanced
glycation end products (AGEs) are a source of increased protein glycation burden, a manifestation of another
hallmark of aging, loss of proteostasis. Methylglyoxal (MGO), a reactive precursor to AGEs, influences the
pathophysiology of insulin resistance (IR) and cellular senescence. A recent study indicates that IR
accelerates ß-cell senescence leading to functional decline in pancreatic tissue and worsening metabolic profile.
Emerging evidence also suggests that the accumulation of senescent cells in adipose tissue directly regulates
the IR phenotypes. Current investigations established the co-occurrence of these two aging hallmarks. However,
a major gap in our knowledge exists in understanding the interactions between both the hallmarks and the impact
of normal and pathological aging on these interactions. Our long-term goal is to further investigate this emerging
and exciting area of research in the context of tissue-specific communication that dictates interactions among
aging hallmarks. The present proposal will specifically ask the following critical questions: (a) how do these three
hallmarks of aging interact with each other; (b) is there any tissue-specific hierarchy and interdependency
between the three hallmarks in different tissues; (c) can multiple interventions which overcome these hallmarks
of aging show additive protection to slow aging and age-related diseases. Our central hypothesis is that MGO-
induced protein glycation not only acts as an endogenous driver for IR and cellular senescence but also plays a
key role in the interplay between these two hallmarks in the adipose tissue and pancreas. We will test the
hypothesis by pursuing the following Specific Aims: 1) the role of methylglyoxal in inducing senescence in the
pancreatic ß-cells and adipose tissue through protein glycation; 2) the role of methylglyoxal in inducing IR in
adipose tissue or insulin release from pancreatic ß-cells through protein glycation; and 3) investigate the interplay
between MGO-induced protein glycation IR and cellular senescence. Preadipocytes and primary ß-cells will be
used to study the role of MGO in inducing tissue-specific senescence and IR. We will also utilize senolytics to
determine the importance of senescent cells in MGO-induced IR. We will also determine the therapeutic potential
of combing a novel glycation-lowering cocktail, Gly-Low, with or without a senolytic for their impact on
ameliorating IR, senescence, and lifespan in a physiological (high-fat diet) model. A key significance of this work
is helping us understand the interconnectivity among MGO-induced protein glycation burden, IR, and cellular
senescence, thereby shedding light on how these hallmarks interact with each other under stress conditions and
how this knowledge can be used to slow aging and ameliorate age-related diseases.